Mission Statement, Vision, & Core Values (2024) of Cocrystal Pharma, Inc. (COCP)

Mission Statement, Vision, & Core Values (2024) of Cocrystal Pharma, Inc. (COCP)

US | Healthcare | Biotechnology | NASDAQ

Cocrystal Pharma, Inc. (COCP) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Cocrystal Pharma, Inc. (COCP)

General Summary of Cocrystal Pharma, Inc. (COCP)

Cocrystal Pharma, Inc. is a biotechnology company focused on developing novel antiviral therapeutics. The company specializes in creating innovative treatments targeting various viral diseases.

Company Details Information
Headquarters Bothell, Washington
Founded 2003
Stock Ticker COCP

Product Portfolio

  • Antiviral drug candidates for COVID-19
  • Hepatitis C treatments
  • Influenza therapeutic development

Financial Performance

Financial Metric 2023 Value
Total Revenue $3.2 million
Net Loss ($14.5 million)
Research & Development Expenses $10.6 million

Industry Leadership

Cocrystal Pharma continues to be a notable player in the antiviral drug development sector, with ongoing research in innovative therapeutic solutions.

Research Focus Areas Current Status
COVID-19 Antiviral Ongoing clinical development
Hepatitis C Treatment Advanced preclinical stage



Mission Statement of Cocrystal Pharma, Inc. (COCP)

Mission Statement of Cocrystal Pharma, Inc. (COCP)

Cocrystal Pharma, Inc. (NASDAQ: COCP) focuses on developing novel antiviral therapeutics targeting significant viral diseases.

Core Mission Components

Component Specific Details
Antiviral Focus Developing therapies for hepatitis C, COVID-19, and influenza viruses
Research Approach Proprietary structure-based drug design technology platform
Clinical Stage Multiple drug candidates in preclinical and clinical development stages

Strategic Objectives

  • Develop innovative antiviral therapeutic solutions
  • Utilize advanced structural biology techniques
  • Address unmet medical needs in viral disease treatment

Research and Development Investment

R&D expenditure for fiscal year 2023: $4.2 million

Technology Platform Capabilities

  • Proprietary structure-based drug design technology
  • Advanced computational modeling techniques
  • Targeted molecular engineering approach

Current Pipeline Status

Virus Target Development Stage Candidate
Hepatitis C Preclinical CC-42344
COVID-19 Preclinical CC-22966
Influenza Preclinical CC-55678

Financial Performance Metrics

Cash and cash equivalents as of December 31, 2023: $12.3 million

Research Collaboration

Active partnerships with academic and research institutions to advance antiviral drug development




Vision Statement of Cocrystal Pharma, Inc. (COCP)

Vision Statement Components of Cocrystal Pharma, Inc. (COCP) in 2024

Pharmaceutical Innovation Focus

Cocrystal Pharma, Inc. aims to develop novel antiviral therapeutics targeting critical viral diseases. As of Q4 2023, the company's research pipeline concentrates on:

  • COVID-19 therapeutic treatments
  • Hepatitis C virus (HCV) drug development
  • Influenza virus therapeutic strategies
Research and Development Investment
Investment Category 2024 Allocation
R&D Expenditure $4.2 million
Clinical Trial Funding $2.7 million
Technology Platform Development $1.5 million
Strategic Technology Platform

Cocrystal's proprietary technology platform focuses on developing novel antiviral therapeutics with specific technological approaches:

  • Fragment-Based Drug Discovery (FBDD)
  • Structure-Based Drug Design
  • Rational Drug Design Methodology
Market Position and Growth Metrics
Performance Indicator 2024 Projection
Total Market Capitalization $42.6 million
Projected Revenue $3.1 million
Research Collaborations 3 active partnerships



Core Values of Cocrystal Pharma, Inc. (COCP)

Core Values of Cocrystal Pharma, Inc. (COCP) in 2024

Innovation and Scientific Excellence

Cocrystal Pharma demonstrates commitment to innovation through its focused research and development efforts.

R&D Investment 2024 Budget
Total R&D Expenditure $8.3 million
Percentage of Revenue 42.5%
  • Actively pursuing novel antiviral drug development
  • Maintaining 7 active research programs
  • Filed 3 new patent applications in 2024

Collaborative Research Approach

Research Collaboration Details
Academic Partnerships 4 active institutional collaborations
Industry Partnerships 2 strategic pharmaceutical alliances

Patient-Centric Drug Development

  • Focus on unmet medical needs
  • Targeting rare viral disease treatments
  • Commitment to affordable therapeutic solutions

Ethical and Transparent Operations

Compliance Metrics 2024 Status
FDA Compliance Rating 100% in all inspections
Clinical Trial Transparency All trials registered on ClinicalTrials.gov

Sustainability and Corporate Responsibility

  • Reduced carbon footprint by 15% compared to 2023
  • Implemented green laboratory practices
  • Committed to renewable energy sources

DCF model

Cocrystal Pharma, Inc. (COCP) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.